185 related articles for article (PubMed ID: 34509297)
1. Adherence to PARP inhibitor therapy among women with ovarian cancer.
Moss HA; Chen L; Hershman DL; Davidson B; Wright JD
Gynecol Oncol; 2021 Nov; 163(2):262-268. PubMed ID: 34509297
[TBL] [Abstract][Full Text] [Related]
2. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
3. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
4. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
5. Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey.
Kim JH; Lee Y; Kim DY; Kim S; Seo SS; Kang S; Park SY; Lim MC
J Gynecol Oncol; 2024 Jan; 35(1):e3. PubMed ID: 37681357
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Jiang X; Li X; Li W; Bai H; Zhang Z
J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
[TBL] [Abstract][Full Text] [Related]
7. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
8. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
Gallagher JR; Heap KJ; Carroll S; Travers K; Harrow B; Westin SN
Future Oncol; 2019 Dec; 15(36):4197-4206. PubMed ID: 31707856
[No Abstract] [Full Text] [Related]
9. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
10. Niraparib Slows Ovarian Cancer Progression.
Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA
Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
14. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
Rimel BJ; Dockery L; Randall LM; Moore K
Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196
[TBL] [Abstract][Full Text] [Related]
15. Niraparib for the treatment of ovarian cancer.
Kanjanapan Y; Lheureux S; Oza AM
Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
[TBL] [Abstract][Full Text] [Related]
16. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR; Monk BJ; Herrstedt J; Oza AM; Mahner S; Redondo A; Fabbro M; Ledermann JA; Lorusso D; Vergote I; Ben-Baruch NE; Marth C; Mądry R; Christensen RD; Berek JS; Dørum A; Tinker AV; du Bois A; González-Martín A; Follana P; Benigno B; Rosenberg P; Gilbert L; Rimel BJ; Buscema J; Balser JP; Agarwal S; Matulonis UA;
N Engl J Med; 2016 Dec; 375(22):2154-2164. PubMed ID: 27717299
[TBL] [Abstract][Full Text] [Related]
17. [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
Delaye M; Rodrigues M
Bull Cancer; 2021 Apr; 108(4):350-351. PubMed ID: 33641880
[No Abstract] [Full Text] [Related]
18. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
19. Niraparib: A Review in Ovarian Cancer.
Heo YA; Duggan ST
Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors for ovarian cancer.
Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
[No Abstract] [Full Text] [Related]
[Next] [New Search]